Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series

ABSTRACT

Objective: Systemic treatment of advanced pancreatic adenocarcinoma has resulted in increased survival of patients, but real-life data are scarce, particularly in developing countries. This study aims to analyze the survival of patients with locally advanced, unresectable, or metastatic pancreatic cancer and factors related to better survival. Methods: an analytical study with a retrospective and prospective part of data from patients with locally advanced or metastatic pancreatic adenocarcinoma treated between January 2012 to December 2018 in the oncology department of the Real Hospital de Beneficência Portuguesa, in Recife (Brazil). Results: Thirty-five patients were assessed. The median age was 68 years old (71.4% = 65 years old), the majority was male (65.7%), with Eastern Cooperative Oncology Group (ECOG) 0 and 1 (65.7%) and metastatic disease (68.6%). The median overall survival was 13.93 months and was longer for patients with ECOG 0 or 1 (20.4 months; p=0.021), Neutrophil-lymphocyte ratio (NLR) <4 (15.63 months; p=0.029) and who received local therapy (23.68 months; p=0.006). Conclusion: An overall median survival, similar to that of other clinical studies, was observed. Such survival was even better in patients with a good clinical condition (ECOG 0 or 1), low NLR, and who received some local therapy.

RESUMO

Objetivo:O tratamento sistêmico do adenocarcinoma pancreático avançado resultou em aumento da sobrevida dos pacientes, mas os dados da vida real são escassos, principalmente em países em desenvolvimento. Este estudo tem como objetivo analisar a sobrevida de pacientes com câncer de pâncreas localmente avançado, irressecável ou metastático e fatores relacionados a uma melhor sobrevida. Métodos: estudo analítico com parte retrospectiva e prospectiva de dados de pacientes com adenocarcinoma pancreático localmente avançado ou metastático atendidos entre janeiro de 2012 a dezembro de 2018 no serviço de oncologia do Real Hospital Português, Recife, PE, Brasil. Resultados: Trinta e cinco pacientes foram avaliados. A mediana de idade foi de 68 anos (71,4% = 65 anos), a maioria era do sexo masculino (65,7%), com Eastern Cooperative Oncology Group (ECOG) 0 e 1 (65,7%) e doença metastática (68,6%). A sobrevida global mediana foi de 13,93 meses e foi mais longa para pacientes com ECOG 0 ou 1 (20,4 meses; p = 0,021), proporção de neutrófilos-linfócitos (NLR) <4 (15,63 meses; p = 0,029) e que receberam terapia local (23,68 meses; p = 0,006). Conclusão: Foi observada uma sobrevida global mediana, semelhante à de outros estudos clínicos. Essa sobrevida foi ainda melhor em pacientes com bom estado clínico (ECOG 0 ou 1), baixo nível de NLR e que receberam alguma terapia local.

Keywords:

Survival Analysis - Prognosis - Antineoplastic Combined Chemotherapy Protocols - Pancreatic Neoplasms - Adenocarcinoma

Descritores:

Análise de sobrevivência - Prognóstico - Antineoplastic Combined Chemotherapy Protocols - Neoplasias pancreáticas - Adenocarcinoma

Publikationsverlauf

Eingereicht: 15. Februar 2020

Angenommen: 24. Juli 2020

Artikel online veröffentlicht:
27. August 2020

• REFERENCES

• International Agency of Research on Cancer. Estimated number of new cases in 2018, Asia, Indonesia, both sexes, all ages. World Heal Organ 2018; 876: 2018
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res [Internet] 2014; Jun; 1; 74 (11) 2913-2921 Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-14-0155
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M. et al Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med [Internet] 2013; Oct; 31; 369 (18) 1691-1703 Available from: http://www.nejm.org/doi/10.1056/NEJMoa1304369
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y. et al FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med [Internet] 2011; May; 12; 364 (19) 1817-1825 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21561347
• Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet [Internet] 2016; 35: 185-198 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27249699
• Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F. et al Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol [Internet] 2016; Dec; 6 (07) 982-988 Available from: http://jgo.amegroups.com/article/view/8283/9417
• Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C. et al Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist [Internet] 2015; Feb; 1; 20 (02) 143-150 Available from: http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2014-0394
• Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta [Internet] 2018; Apr; 479: 181-189 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0009898118300329
• Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P. et al Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev [Internet] 2017; Jul; 58: 1-13 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0305737217300853
• Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y. Prognostic value of platelet-to- lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther [Internet] 2018; 11: 1899-1908 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29670365
• Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT. et al The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol [Internet] 2015; Jul; 22 (07) 2352-2358 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25564157
• Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA. et al Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys [Internet] 2013; Jul; 1; 86 (03) 516-522 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23562768
• Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L. et al Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol [Internet] 2013; Mar; 1; 8: 44 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23452509
• Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P. et al Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA [Internet] 2016; May; 3; 315 (17) 1844 Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.4324
• Mota JM, Silva AHC, Franco AS, Talans A, Ribeiro- Ferreira F, Castria TB de. et al FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single- institution experience. . Brazilian J Oncol [Internet]. 2018;14(47). Available from: http://brazilianjournalofoncology.com.br/details/38/en-US
• Skelton WP, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S. et al Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer [Internet] 2018; Mar; 7; 49 (01) 1-8 Available from: http://link.springer.com/10.1007/s12029-017-0021-z
• Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N. et al FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology [Internet] 2019; Mar; 19 (02) 296-301 Available from: https://linkinghub.elsevier.com/retrieve/pii/S142439031930002X
• Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P. et al Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Ann Surg Oncol [Internet] 2015; Apr; 22 (04) 1153-1159 Available from: http://link.springer.com/10.1245/s10434-014-4225-1
• Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A. et al Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers (Basel) [Internet] 2019; Jul; 13; 11 (07) 981 Available from: https://www.mdpi.com/2072-6694/11/7/981
• Le N, Sund M, Vinci A, Beyer G, Ashan Javed M, Krug S. et al Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis [Internet] 2016; Mar; 48 (03) 223-230 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1590865815006908
• Pellei C MA. Prognostic Factors in Pancreatic Cancer: The Role of Perineural, Vascular and Lymphatic Invasion and of Ca19-9. . J Gastrointest Dig Syst [Internet]. 2013;03(3). Available from: https://www.omicsonline.org/prognostic-factors-in-pancreatic-cancer-the-role-of-perineural-vascular-and-lymphatic-invasion-and-of-ca2161-069X-3-134.php?aid=17559
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol [Internet] 2012; Jun; 3 (02) 105-119 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22811878
• Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci [Internet] 2017; Mar; 20; 18 (03) 667 Available from: http://www.mdpi.com/1422-0067/18/3/667
• Hua Y-Q, Wang P, Zhu X-Y, Shen Y-H, Wang K, Shi W-D. et al Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology [Internet] 17 (06) 967-973 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29129384